10-Q: Knowles Reports Strong Q2 2025 Earnings, Driven by Continuing Operations Growth

Knowles Corporation reported a significant improvement in net earnings for Q2 2025, driven by revenue growth in its continuing operations and the absence of losses from its divested Consumer MEMS Microphones segment.

Summary

• Revenues for the second quarter of 2025 increased by 7.9% to $145.9 million, up from $135.2 million in the second quarter of 2024.
• Net earnings for the second quarter of 2025 were $7.8 million, a substantial improvement from a net loss of $259.3 million in the second quarter of 2024, primarily due to the reclassification of the Consumer MEMS Microphones (CMM) segment as discontinued operations.
• Diluted earnings per share from continuing operations rose to $0.09 in the second quarter of 2025 from $0.05 in the second quarter of 2024.
• Adjusted free cash flow for the six months ended June 30, 2025, increased to $57.9 million, up from $36.5 million in the prior year period.
• The Precision Devices segment saw revenues increase by 5.9% to $78.5 million and Adjusted EBIT grow by $2.1 million to $13.9 million in the second quarter of 2025.
• The MedTech & Specialty Audio segment's revenues increased by 10.3% to $67.4 million in the second quarter of 2025, though its EBIT decreased by $3.1 million to $21.0 million due to an impairment charge and other factors.
• An impairment charge of $3.6 million was recorded in the second quarter of 2025 for certain machinery and equipment in the MedTech & Specialty Audio segment.
• The company repurchased $35.0 million of common stock during the six months ended June 30, 2025, with $159.0 million remaining under the current authorization.

Sentiment

Score: 8

Explanation: The company demonstrated strong financial improvement in continuing operations, driven by revenue growth and effective cost management, particularly after the strategic divestiture of the CMM segment. While gross profit margin saw a slight decline and the MSA segment faced some headwinds, the overall financial health, cash flow generation, and strategic focus on high-growth industrial and medical markets are positive indicators. The increased share repurchase authorization also signals confidence in future performance and commitment to shareholder returns.

Positives

• Net earnings significantly improved to $7.8 million in Q2 2025 from a net loss of $259.3 million in Q2 2024, primarily due to the CMM divestiture.
• Revenue growth from continuing operations was strong, increasing by 7.9% in Q2 2025 and 3.6% for the six months ended June 30, 2025.
• Diluted EPS from continuing operations increased to $0.09 in Q2 2025 from $0.05 in Q2 2024.
• Adjusted free cash flow increased by $21.4 million to $57.9 million for the six months ended June 30, 2025, representing 20.8% of revenues.
• Interest expense decreased by $2.1 million in Q2 2025 and $3.8 million for the six months ended June 30, 2025, due to a lower outstanding revolving credit facility balance and lower imputed interest on the Seller Note.
• The Precision Devices segment demonstrated strong performance with 5.9% revenue growth and a 33.9% increase in Adjusted EBIT to $13.9 million in Q2 2025.
• The Board of Directors authorized an additional $150.0 million for the share repurchase program on February 13, 2025, with $159.0 million remaining authorized at June 30, 2025.
• The company is in compliance with all debt covenants.
• Increased bookings and backlog for capacitor products in the Precision Devices segment indicate normalizing industrial market inventory levels.

Negatives

• Gross profit margin decreased to 41.5% in Q2 2025 from 42.8% in Q2 2024, primarily due to impairment charges, unfavorable product mix, unfavorable inventory reserve adjustments, and production inefficiencies in the Cornell Dubilier (CD) business.
• The MedTech & Specialty Audio segment's EBIT decreased by $3.1 million to $21.0 million in Q2 2025, mainly due to impairment charges, lower average pricing on mature products, unfavorable product mix, higher factory costs, and the impact of higher shipping volumes of lower margin metal can products to Syntiant.
• Net cash provided by operating activities decreased to $37.7 million for the six months ended June 30, 2025, from $42.2 million in the prior year, primarily due to $29.3 million of payments to settle supplier obligations and separation costs related to the CMM business and higher restructuring payments.
• An impairment charge of $3.6 million was recorded in Q2 2025 for certain machinery and equipment.
• Identified and corrected an understatement of stock-based compensation expense for prior years, which decreased earnings by $1.0 million for the six months ended June 30, 2025.
• Identified and corrected an overstatement of the gain on CMM disposal by $1.3 million (net of tax) in 2024.

Risks

• Ability to achieve expected strategic and financial benefits from the CMM divestiture.
• Difficulties or delays in realizing expected synergies from acquisitions.
• Fluctuations in stock market price, operating results, and cash flows.
• Ability to prevent or identify quality issues in products or promptly remedy them.
• Risks associated with increasing inventories in advance of anticipated customer orders.
• Global economic instability, including inflation, rising interest rates, pandemics, and geopolitical uncertainties.
• Impact of changes to laws and regulations affecting product or service offerings.
• Ability to achieve reductions in operating expenses.
• Ability to qualify products and facilities with customers.
• Ability to obtain, enforce, defend, or monetize intellectual property rights, including potential retaliatory legal proceedings.
• Disruption caused by cybersecurity incidents, including cyber attacks, cyber breaches, theft, or other unauthorized access.
• Increases in costs or availability issues of critical raw materials and components.
• Challenges in managing new product ramps and introductions for customers.
• Dependence on a limited number of large customers.
• Increasing competition and new market entrants for products.
• Ability to develop new or enhanced products or technologies in a timely manner that achieve market acceptance.
• Escalating international trade tensions, new or increased tariffs, and trade wars among countries.
• Financial risks, including risks relating to currency fluctuations, credit risks, and fluctuations in the market value of the company.
• Potential impairment of certain intangible or long-lived assets due to a sustained decline in stock price and market capitalization.
• Market risk associated with fluctuations in commodity prices, particularly for various precious metals used in manufacturing operations.
• Changes in tax laws, changes in tax rates, and exposure to additional tax liabilities.

Future Outlook

The company expects capital expenditures to be in the range of 4% to 6% of revenues in 2025. It does not anticipate the new U.S. universal baseline tariff of 10% (announced April 2, 2025) or the 'One Big Beautiful Bill Act' (signed July 4, 2025) to have a material impact on its operations or financial statements in 2025 or subsequent years. The company anticipates remaining in compliance with all debt covenants over the next twelve months, and notes that normalizing industrial market inventory levels are leading to increased bookings and backlog for capacitor products in the Precision Devices segment.

Management Comments

• "We are optimizing operations and leveraging existing programs and strategies to reduce the impact from tariffs."
• "We are taking measures to control costs and implementing pricing actions designed to mitigate the risk these policies may have on our revenues and operations."
• "As inventory levels in the industrial markets have recently begun to normalize, our Precision Devices segment has experienced increased bookings for the past three quarters."
• "With bookings increasing we have seen backlog across our capacitor products increase for the past three quarters."
• "We believe that our future cash flow from operations and access to capital markets will provide adequate resources to fund our working capital needs, capital expenditures, strategic investments, and share repurchases."
• "Management will continue to reassess our need to repatriate the earnings of our foreign subsidiaries."

Industry Context

The company is actively transforming into an industrial technology company, focusing its efforts on the Precision Devices and MedTech & Specialty Audio segments, which primarily serve the defense, medtech, industrial, and electrification markets. This strategic shift aligns with a broader industry trend towards specialization in high-value, critical components for resilient and growing sectors. The reported normalization of inventory levels in industrial markets and subsequent increase in bookings and backlog for capacitor products suggest a positive demand environment, potentially indicating a broader recovery or stabilization within the industrial component sector.

Corporate Governance

Legal Proceedings

• Involved in various legal proceedings and claims arising in the ordinary course of business, primarily related to commercial, warranty, employment, and intellectual property matters.
• Believes the disposition of these legal proceedings or claims, individually or in the aggregate, after taking into account recorded accruals and insurance coverage, will not have a material adverse effect on its cash flow, results of operations, or financial condition.
• May provide contractual indemnities for certain losses arising from claims that its products infringe on the intellectual property of others, but historically has not made significant payments under such arrangements.

Related Party Transactions

• Received Series D-2 preferred stock of Syntiant with a fair value of $77.2 million as partial consideration for the sale of the CMM segment on December 27, 2024.
• Provided financing of $6.4 million to Syntiant, with a balance of $5.9 million remaining as of June 30, 2025.
• Shares in certain separation costs with Syntiant, with a credit of $8.7 million remaining at June 30, 2025.
• Leases portions of its facilities to Syntiant, with $1.2 million in lease payments applied to the separation credit.
• Subleases portions of its manufacturing facilities to Syntiant at cost, with $5.3 million of operating lease right-of-use assets subleased at June 30, 2025.
• Recognized $8.3 million in revenue from transactions with Syntiant for the six months ended June 30, 2025, reflected in the MedTech & Specialty Audio segment.
• Receivables, net include $3.2 million due from Syntiant at June 30, 2025.
• Engaged with Syntiant to sell certain machinery and equipment associated with the MedTech & Specialty Audio segment for a nominal expected selling price, resulting in a $3.6 million impairment charge in Q2 2025.

Stakeholder Impact

• Shareholders: Benefited from increased diluted EPS from continuing operations and an expanded share repurchase program, signaling commitment to shareholder returns and long-term value creation.
• Employees: Affected by headcount reductions related to restructuring actions following the CMM divestiture, aimed at rightsizing operating expenses.
• Customers: Benefited from increased shipping volumes in specialty audio and hearing health markets, and higher demand in electrification and defense markets.
• Creditors: The company remains in compliance with all debt covenants, indicating financial stability and ability to meet obligations.

Next Steps

• Completion of the sale of certain machinery and equipment associated with the MedTech & Specialty Audio segment to Syntiant in the third quarter of 2025.
• Continued assessment and modeling of the impact of the 'One Big Beautiful Bill Act' as the year progresses.
• Repayment of the remaining $72.7 million balance of the Seller Note on November 1, 2025.
• Ongoing evaluation of market conditions and other factors to determine the timing and amount of future share repurchases.
• Continued investment in development activities in both Precision Devices and MedTech & Specialty Audio segments.

Key Dates

Recommendation

Knowles Corporation's Q2 2025 results demonstrate a strong turnaround and successful execution of its strategic transformation. The divestiture of the CMM segment has significantly improved net earnings and allowed for a sharper focus on higher-margin, specialized markets like medtech, defense, and industrial. The growth in continuing operations revenue, coupled with a substantial increase in adjusted free cash flow, indicates robust operational health and liquidity. While gross profit margin saw a slight dip due to specific factors, the overall trend in profitability and the company's commitment to shareholder returns through an expanded share repurchase program are highly positive. The normalization of industrial market inventory levels and increasing backlog in the Precision Devices segment suggest a favorable demand environment ahead. These factors, combined with prudent debt management, position Knowles for continued growth and make it an attractive investment.

Keywords

Specialty Electronic Components, MedTech, Defense, Industrial Markets, Capacitors, RF Filters, Microwave Filters, Microphones, Balanced Armature Speakers, SEC Filing, Quarterly Report, Financial Results, Earnings, Revenue, Cash Flow, Share Repurchase, Divestiture, Syntiant, Precision Devices, MedTech & Specialty Audio, Corporate Governance, Risk Management